A Phase 1, Open-label, Single Dose, Crossover Study to Assess the Relative Bioavailability of Emraclidine Formulations in Healthy Adult Subjects

Inclusion Criteria: * Body mass index of 18.5 to 32.0 kg/m2, inclusive. * Total body weight \>= 50 kg. Exclusion Criteria: * History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement. * Vital sign measurements, at Screening and Check-in: * Systolic blood pressure \>= 140 mmHg or \< 100 mmHg…